Patents by Inventor Varghese Palath

Varghese Palath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detection of EphA3 as a Marker of the Presence of a Solid Tumor
    Publication number: 20170335001
    Abstract: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
    Type: Application
    Filed: July 8, 2016
    Publication date: November 23, 2017
    Inventors: Martin Lackmann, Andrew Mark Scott, Catherine To, Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
  • Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
    Publication number: 20170226227
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: September 14, 2016
    Publication date: August 10, 2017
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone Marrow
    Publication number: 20150329647
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Application
    Filed: July 30, 2015
    Publication date: November 19, 2015
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
    Patent number: 9109032
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: August 18, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • Anti-EMR1 antibodies
    Patent number: 9045539
    Abstract: The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: June 2, 2015
    Assignee: Kalobios Pharmaceuticals, Inc.
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • TREATMENT OF LEUKEMIAS AND CHRONIC MYELOPROLIFERATIVE DISEASES WITH ANTIBODIES TO EPHA3
    Publication number: 20140370010
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
    Patent number: 8834870
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: September 16, 2014
    Assignee: Kalobios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Methods of treating dementia using a GM-CSF antagonist
    Patent number: 8398972
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 19, 2013
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • ANTI-EMR1 ANTIBODIES
    Publication number: 20130064826
    Abstract: The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 14, 2013
    Inventors: Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
  • METHODS OF TREATING HEMATOLOGICAL PROLIFERATIVE DISORDERS BY TARGETING EPHA3 EXPRESSED ON ABERRANT VASCULATURE IN BONE MARROW
    Publication number: 20130039907
    Abstract: The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.
    Type: Application
    Filed: August 10, 2012
    Publication date: February 14, 2013
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Geoffrey T. Yarranton, Varghese Palath, Christopher R. Bebbington, Mark Baer
  • DETECTION OF EPHA3 AS A MARKER OF THE PRESENCE OF A SOLID TUMOR
    Publication number: 20110318304
    Abstract: The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: Martin Lackmann, Andrew Mark Scott, Catherine To, Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
  • EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA
    Publication number: 20110243934
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of multiple myeloma.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 6, 2011
    Applicant: KaloBios Pharmaceuticals Inc.
    Inventors: Varghese Palath, Christopher R. Bebbington
  • Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3
    Publication number: 20100226930
    Abstract: The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 9, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST
    Publication number: 20100215650
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: February 11, 2010
    Publication date: August 26, 2010
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • Compositions and methods for treating haematological proliferative disorders
    Publication number: 20080003224
    Abstract: The disclosure relates to antibodies immunoreactive with CD45RA+ hematopoietic tumor cells (HTCs), hybridomas producing such antibodies, and methods of using the antibodies, particularly as therapeutic treatments for conditions or diseases characterized by CD45RA+ HTCs.
    Type: Application
    Filed: January 29, 2007
    Publication date: January 3, 2008
    Applicant: Cellerant Therapeutics, Inc.
    Inventors: Timothy Fong, Varghese Palath, R. Tesi, Hoang Tran, Irving Weissman